Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
50.48
-0.97 (-1.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Top 3 Health Care Stocks You'll Regret Missing In October
↗
October 21, 2025
Via
Benzinga
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results
↗
October 20, 2025
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients.
Via
Benzinga
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
October 20, 2025
Via
Benzinga
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
↗
October 20, 2025
Via
Benzinga
17 Analysts Have This To Say About Exelixis
↗
September 17, 2025
Via
Benzinga
Peering Into Exelixis's Recent Short Interest
↗
September 15, 2025
Via
Benzinga
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
October 20, 2025
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
October 18, 2025
From
Exelixis, Inc.
Via
Business Wire
Is the Market Bullish or Bearish on Exelixis?
↗
August 26, 2025
Via
Benzinga
The Ultimate Biotech Stock to Buy With $50 Right Now
↗
October 14, 2025
This innovative drugmaker still has plenty of upside potential.
Via
The Motley Fool
EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening
↗
October 07, 2025
Exelixis (EXEL) presents a strong value investment case with low P/E ratios, zero debt, robust profitability, and solid growth in the biotech sector.
Via
Chartmill
EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock
↗
October 04, 2025
Discover EXELIXIS INC (EXEL), an affordable growth stock with strong financials, impressive earnings, and a discounted valuation in the biotech sector.
Via
Chartmill
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
↗
September 30, 2025
Both should have significant catalysts by the end of the decade.
Via
The Motley Fool
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Undervalued Stock with Strong Fundamentals
↗
September 15, 2025
EXELIXIS (EXEL) emerges as a top value stock with strong fundamentals: undervalued, zero debt, high profitability, and solid growth in the biotech sector.
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
September 14, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Exelixis Inc (NASDAQ:EXEL) Embodies the Affordable Growth Investment Strategy
↗
September 13, 2025
Exelixis (EXEL) offers affordable growth with strong oncology revenue, high profitability, a robust balance sheet, and attractive valuation metrics.
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
September 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
September 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
September 02, 2025
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
September 02, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
August 29, 2025
From
Exelixis, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
August 29, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
August 27, 2025
From
Exelixis, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
August 25, 2025
From
Pomerantz LLP
Via
GlobeNewswire
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity
↗
August 25, 2025
Exelixis (EXEL) is a strong value investing candidate, trading below intrinsic value with a solid financial profile, high profitability, and strong growth prospects.
Via
Chartmill
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Growth at a Reasonable Price (GARP) Stock
↗
August 22, 2025
EXELIXIS INC (EXEL) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity.
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
August 21, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
August 17, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Exelixis Inc (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Setup
↗
August 16, 2025
Exelixis (EXEL) is a strong growth stock with solid fundamentals—17.5% revenue growth, high profitability, and no debt—plus a bullish technical setup, signaling a potential breakout opportunity.
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
August 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
